These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17010175)

  • 1. Follicular rash during therapy with erlotinib (Tarceva).
    Gerdes S; Mrowietz U
    J Dtsch Dermatol Ges; 2006 Oct; 4(10):855-7. PubMed ID: 17010175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erlotinib-induced scalp perifolliculitis.
    Rallis E; Petronic-Rosic V; Korfitis C
    Skinmed; 2012; 10(2):70-1. PubMed ID: 22545319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
    Kiyohara Y; Yamazaki N; Kishi A
    J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
    Acharya J; Lyon C; Bottomley DM
    J Am Acad Dermatol; 2009 Jan; 60(1):154-7. PubMed ID: 19103369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
    Benomar S; Boutayeb S; Afifi Y; Hamada S; Bouhllab J; Hassam B; Errihanni H
    Dermatol Online J; 2009 Nov; 15(11):2. PubMed ID: 19951638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
    Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
    Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib-induced pustular eruption.
    Cusano F; Ferrara G; Barletta E; Ingordo V
    G Ital Dermatol Venereol; 2009 Feb; 144(1):93-6. PubMed ID: 19218915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
    Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
    [No Abstract]   [Full Text] [Related]  

  • 10. [Erlotinib-induced acneiform rash not affecting previously irradiated skin].
    Eguren C; Domínguez-Fernández I; Santiago-Sánchez-Mateos DI; García-Díez A
    Actas Dermosifiliogr; 2010 Mar; 101(2):186-7. PubMed ID: 20223168
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 12. Pulmonary fibrosis in a patient treated with erlotinib.
    Bach JP; Kiessling AM; Kleinhans A; Faoro C; Gorg C; Riera-Knorrenschild J; Schwella N; Wagner HJ; Neubauer A
    Onkologie; 2006 Jul; 29(7):342-3. PubMed ID: 16874020
    [No Abstract]   [Full Text] [Related]  

  • 13. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
    Gridelli C; Maione P; Bareschino MA; Schettino C; Sacco PC; Ambrosio R; Barbato V; Falanga M; Rossi A
    Anticancer Res; 2010 Apr; 30(4):1301-10. PubMed ID: 20530444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
    Grossi F; Rijavec E; Dal Bello MG; Defferrari C; Brianti A; Barletta G; Genova C; Murolo C; Cosso M; Fontanini G; Boldrini L; Truini M; Pronzato P
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1407-12. PubMed ID: 22349923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
    Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
    Lung Cancer; 2012 Oct; 78(1):8-15. PubMed ID: 22795701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient.
    Tsubata Y; Hamada A; Sutani A; Isobe T
    J Cancer Res Ther; 2012; 8(1):154-6. PubMed ID: 22531540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tyrosine kinase inhibitor erlotinib (Tarceva) improves survival of patients with multiple previous treatments].
    Krankenpfl J; 2004; 42(5-6):158. PubMed ID: 15527222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.